There is a striking imbalance in global biotech investment, with the United States commanding an overwhelming 80% of all funding. With most new therapies today originating from biotech companies, this significant disparity highlights the urgent need for Europe to strengthen its position in the biotech ecosystem. The EIC Scaling Club, which counts Biovance Capital among its partners, is working to shift this imbalance and create a more equitable distribution of investment opportunities.
One such initiative by the Club is the collection, together with its members and partners, of insights on the most relevant company challenges, and most promising market opportunities in the biotech space. Their latest report, which counted with the participation of Biovance General Partner João Incio, can be found here.